Xingcong Ma
Impact in
- Oncology top 10%
- CAR-T cell therapy research
- Cancer Immunotherapy and Biomarkers
- Cancer Cells and Metastasis
- Immunology top 10%
- Immune cells in cancer
- Immune Cell Function and Interaction
- Immunotherapy and Immune Responses
Papers in
-
- Circular RNAs in diseases 3
- Oncology 9
- CAR-T cell therapy research 4
- Co-authors
- Wanjun Yan (7 shared papers)Shuqun Zhang (5 shared papers)Xiaoyao Zhao (4 shared papers)Shuqun Zhang (11 shared papers)Xiaoyan Gao (5 shared papers)Xixi Zhao (5 shared papers)Jingkun Qu (2 shared papers)Jizhao Wang (2 shared papers)
- Journals
- Oncotarget (3 papers)Drug Design Development and Therapy (2 papers)International Journal of Surgery (1 paper)Medicine (1 paper)International Journal of Pharmaceutics (1 paper)
- Partner nations
- ChinaUnited States
In The Last Decade
Xingcong Ma
19 papers receiving 907 citations
Peers
Comparison fields: 5 of 76
- Oncology 400
- Immunology 293
- Cancer Research 146
- Pharmacology 140
- Health Informatics 11
Countries citing papers authored by Xingcong Ma
This map shows the geographic impact of Xingcong Ma's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xingcong Ma with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xingcong Ma more than expected).
Fields of papers citing papers by Xingcong Ma
This network shows the impact of papers produced by Xingcong Ma. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xingcong Ma. The network helps show where Xingcong Ma may publish in the future.
Co-authors
The 25 scholars most cited alongside Xingcong Ma, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 24 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2017 | 252 | |
| 2 | 2020 | 197 | |
| 3 | 2018 | 185 | |
| 4 | 2016 | 104 | |
| 5 | Baicalein suppress EMT of breast cancer by mediating tumor-associated macrophages polarization. | 2018 | 50 |
| 6 | 2016 | 27 | |
| 7 | 2020 | 17 | |
| 8 | 2017 | 13 | |
| 9 | 2024 | 10 | |
| 10 | 2017 | 10 | |
| 11 | 2016 | 9 | |
| 12 | 2021 | 9 | |
| 13 | 2023 | 8 | |
| 14 | 2023 | 8 | |
| 15 | 2023 | 6 | |
| 16 | 2025 | 5 | |
| 17 | 2024 | 5 | |
| 18 | 2024 | 3 | |
| 19 | 2024 | 1 | |
| 20 | 2025 | 0 |
About Xingcong Ma
Xingcong Ma is a scholar working on Molecular Biology, Oncology, Cancer Research, Genetics and Immunology, having authored 24 papers that have together received 919 indexed citations. Recurring topics across this work include CAR-T cell therapy research (4 papers), BRCA gene mutations in cancer (4 papers), MicroRNA in disease regulation (3 papers), Cancer-related molecular mechanisms research (3 papers), Circular RNAs in diseases (3 papers), Flavonoids in Medical Research (3 papers), Breast Cancer Treatment Studies (2 papers) and AI in cancer detection (2 papers). The work is most often cited by research in Oncology (400 citations), Immunology (293 citations), Cancer Research (146 citations), Pharmacology (140 citations) and Health Informatics (11 citations). Xingcong Ma has collaborated with scholars based in China and United States. Frequent co-authors include Wanjun Yan, Shuqun Zhang, Xiaoyao Zhao, Shuqun Zhang, Xiaoyan Gao, Xixi Zhao, Jingkun Qu, Jizhao Wang, Wen Wang and Yuchen Sun. Their work appears in journals such as Oncotarget, Drug Design Development and Therapy, International Journal of Surgery, Medicine and International Journal of Pharmaceutics.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.